OTCPK:TLTF.F

Stock Analysis Report

Executive Summary

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has Theralase Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

TLTF.F

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

-35.9%

TLTF.F

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: TLTF.F underperformed the US Medical Equipment industry which returned 10% over the past year.

Return vs Market: TLTF.F underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

TLTF.FIndustryMarket
7 Day-4.2%3.2%3.4%
30 Day-11.7%-1.8%-1.0%
90 Day-45.9%-0.4%-0.4%
1 Year-35.9%-35.9%10.9%10.0%7.7%5.4%
3 Year-42.1%-42.1%69.9%64.8%46.2%36.8%
5 Year-40.8%-40.8%128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is Theralase Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Theralase Technologies undervalued compared to its fair value and its price relative to the market?

12.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate TLTF.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate TLTF.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TLTF.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: TLTF.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate TLTF.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLTF.F is overvalued based on its PB Ratio (12x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Theralase Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLTF.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TLTF.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TLTF.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TLTF.F's revenue (55.8% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: TLTF.F's revenue (55.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: TLTF.F is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Theralase Technologies performed over the past 5 years?

-7.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TLTF.F is unprofitable, and losses have increased over the past 5 years at a rate of -7% per year.

Accelerating Growth: Unable to compare TLTF.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLTF.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: TLTF.F has a negative Return on Equity (-159.72%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TLTF.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TLTF.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Theralase Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: TLTF.F's short term assets (CA$3.0M) exceeds its short term liabilities (CA$1.2M)

Long Term Liabilities: TLTF.F's short term assets (3.0M) exceeds its long term liabilities (109.0K)


Debt to Equity History and Analysis

Debt Level: TLTF.F is debt free.

Reducing Debt: TLTF.F has no debt compared to 5 years ago when its debt to equity ratio was 0.08%.


Balance Sheet

Inventory Level: TLTF.F has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if TLTF.F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLTF.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TLTF.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 31.9% each year.


Next Steps

Dividend

What is Theralase Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TLTF.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TLTF.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TLTF.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLTF.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLTF.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Theralase Technologies's salary, the management and board of directors tenure and is there insider trading?

9.5yrs

Average management tenure


CEO

Shawn Shirazi 0

0.7yrs

Tenure

0

Dr. Shawn Shirazi Ph.D., serves as Chief Executive Officer of Drug at Theralase Technologies Inc., since February 25, 2019. Dr. Shirazi served as Senior Director of Global Pre-Commercial Quality and Techni ...


Management Age and Tenure

9.5yrs

Average Tenure

Experienced Management: TLTF.F's management team is seasoned and experienced (9.5 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

Experienced Board: TLTF.F's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: TLTF.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$37,43429 Aug 19
Guy Anderson
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares166,000
Max PriceCA$0.23
BuyCA$37,58426 Aug 19
Kipton Lade
EntityIndividual
Role
Senior Key Executive
Chief Executive Officer of Device
Shares166,666
Max PriceCA$0.23
BuyCA$13,53023 Aug 19
Kristina Hachey
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares60,000
Max PriceCA$0.23
BuyCA$24,80623 Aug 19
Roger Dumoulin-White
EntityIndividual
Role
Other Key Executive
Director of Business Development
Shares110,000
Max PriceCA$0.23
BuyCA$56,79120 Feb 19
Parkview Financial LLC., Asset Management Arm
EntityCompany
Shares214,286
Max PriceCA$0.27
BuyCA$2,65016 Jan 19
Randy Bruder
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceCA$0.27
BuyCA$26,50209 Jan 19
Kristina Hachey
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.27
BuyCA$53,00509 Jan 19
Roger Dumoulin-White
EntityIndividual
Role
Other Key Executive
Director of Business Development
Shares200,000
Max PriceCA$0.27

Ownership Breakdown


Management Team

  • James Andrews (76yo)

    Chairman of Medical & Scientific Advisory Board and Medical Director

    • Tenure: 0yrs
  • Kristina Hachey

    CFO & Director

    • Tenure: 0.3yrs
    • Compensation: CA$200.00k
  • Roger Dumoulin-White

    Director of Business Development

    • Tenure: 0yrs
    • Compensation: CA$300.80k
  • David Groves

    President of World Trade Division

    • Tenure: 12.9yrs
  • Shawn Shirazi

    Chief Executive Officer of Drug

    • Tenure: 0.7yrs
  • Lori Leach

    Marketing & Media Relations Consultant

    • Tenure: 9.8yrs
  • Vaughn Wyant

    Marketing & Media Relations Consultant

    • Tenure: 9.8yrs
  • Terry Ruch

    Equine Medical Consultant

    • Tenure: 9.2yrs
  • Arkady Mandel

    Chief Scientific Officer & Director

    • Tenure: 1.3yrs
    • Compensation: CA$291.98k
  • Kipton Lade

    Chief Executive Officer of Device

    • Tenure: 0.7yrs

Board Members

  • James Andrews (76yo)

    Chairman of Medical & Scientific Advisory Board and Medical Director

    • Tenure: 0yrs
  • Kristina Hachey

    CFO & Director

    • Tenure: 0.3yrs
    • Compensation: CA$200.00k
  • Randy Bruder

    Independent Director

    • Tenure: 11.8yrs
    • Compensation: CA$6.25k
  • Arkady Mandel

    Chief Scientific Officer & Director

    • Tenure: 1.3yrs
    • Compensation: CA$291.98k
  • Michael Jewett

    Member of Medical & Scientific Advisory Board

    • Tenure: 6.8yrs
  • Matt Perraton

    Independent Director

    • Tenure: 6.7yrs
    • Compensation: CA$6.25k
  • Guy Anderson

    Independent Chairman of the Board

    • Tenure: 0yrs
    • Compensation: CA$6.25k
  • Lothar Lilge

    Member of Medical & Scientific Advisory Board

    • Tenure: 0yrs
  • Ashish Kamat

    Member of Medical & Scientific Advisory Board

    • Tenure: 4.8yrs
  • Michael O'Donnell

    Member of Medical & Scientific Advisory Board

    • Tenure: 4.8yrs

Company Information

Theralase Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theralase Technologies Inc.
  • Ticker: TLTF.F
  • Exchange: OTCPK
  • Founded: 1995
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$42.898m
  • Listing Market Cap: CA$32.489m
  • Shares outstanding: 204.28m
  • Website: https://www.theralase.com

Number of Employees


Location

  • Theralase Technologies Inc.
  • 41 Hollinger Road
  • Toronto
  • Ontario
  • M4B 3G4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TLTTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 1996
TLTF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 1996
TTXDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 1996

Biography

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various can ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:30
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.